Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients

Introduction: Epidermal growth factor receptor (EGFR) mutated NSCLC is best treated using an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR overexpression and mutation in NSCLC can be determined using radiolabeled EGFR TKI PET/CT. However, recent research has shown a si...

ver descrição completa

Detalhes bibliográficos

Principais autores:	I. H. Bartelink, E. A. van de Stadt, A. F. Leeuwerik, V. L. J. L. Thijssen, J. R. I. Hupsel, J. F. van den Nieuwendijk, I. Bahce, M. Yaqub, N. H. Hendrikse
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2022-06-01
Colecção:	Pharmaceuticals
Assuntos:	NSCLC EGFR TKI PBPK modeling PET/CT
Acesso em linha:	https://www.mdpi.com/1424-8247/15/7/796
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!